Companies

Dr Reddy’s: Better product mix, cost control boost profitability

Nalinakanthi V BL Research Bureau | Updated on January 24, 2018 Published on July 30, 2015

Dr Reddy’s managed to improve its operating profit margin by 2.8 percentage points to 26.6 per cent in the June quarter, compared to the same period last year. This was on three counts.

First, healthy growth in its global generics segment on the back of a good show in key markets such as the US and India helped the company’s profitability.

Strong ramp up in sales and market share of products launched in 2014-15, such as valganciclovir and sirolimus, as well as injectable products, helped the 14 per cent growth in revenues from the US market.

This helped Dr Reddy’s sustain growth momentum in this geography, amidst slowdown in the pace of new approvals by the US drug regulator over the last several months. In the home market, higher prescription share and new product launches enabled the company achieve 19 per cent revenue growth.

Consolidation of UCB’s India business with Dr Reddy’s has been completed and synergies from the merger should accrue in the forthcoming quarters.

Second, the company’s decision to consciously scale down low margin products in its pharma services and active ingredients business (PSAI) also boosted profitability. The segment’s gross profit margin (sales minus raw material cost is gross profit) improved by 1.4 percentage points to 23.7 per cent.

Third, Dr Reddy’s efforts to optimise manufacturing and sales overheads also played a role in improving profitability. The company’s selling and administration costs rose by a modest 3 per cent, slower than the 7 per cent growth in revenues.

Published on July 30, 2015

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.